PDCD1 and cancer: The efficacy of dostarlimab, a humanized PD-1 monoclonal antibody, was also investigated for MSI-H/dMMR cancers in a nonrandomized, multicenter, multicohort study (GARNET trial: NCT02715284) [65,66].